Author

F. van Maldegem

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Approach:experimental assay· 2 Approach:microscopy & imaging analysis· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Moore· 3 shared E. Mugarza· 3 shared J. Downward· 3 shared K. Valand· 3 shared M. Cole· 3 shared S. Rana· 3 shared C. Swanton· 2 shared E. Colliver· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Moore

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

M. Cole, P. Anastasiou, C. Lee, C. Moore, E. Mugarza, M. Jones, K. Valand, S. Rana, E. Colliver, M. Angelova, K. Enfield, A. Magness, A. Mullokandov, G. Kelly, T. de Gruijl, , F. van Maldegem

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

bioRxiv · Apr 11, 2024Cancer Biology

Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. L. Sopena, P. East, R. Ambler, P. Anastasiou, P. R. Clavijo, K. Valand, M. Cole, M. Molina-Arcas, J. Downward

KRASG12C inhibition enhances anti-tumour immunity in immunogenic lung cancers by upregulating interferon signaling through Myc repression, but only synergizes with immune checkpoint blockade in highly immunogenic models.

bioRxiv · Oct 18, 2021Cancer Biology

Characterisation of tumour immune microenvironment remodelling following oncogene inhibition in preclinical studies using an optimised imaging mass cytometry workflow

F. van Maldegem, K. Valand, M. Cole, H. Patel, M. Angelova, S. Rana, E. Colliver, K. Enfield, N. Bah, V. Tsang, E. Mugarza, C. Moore, P. Hobson, D. Levi, M. Molina, , J. Downward

The paper optimises an imaging mass cytometry workflow to study TME remodelling in mouse models after KRAS G12C inhibitor treatment.

bioRxiv · Feb 2, 2021Cancer Biology